Emerging Treatment Modalities in Metastatic Breast Cancer: Highlights from SABCS 2022 and Beyond

Paolo Tarantino, MD, provides an overview of ER-positive, HER2-negative metastatic breast cancer (ER+/HER2- mBC), highlighting the prevalence, patient populations, and the typical prognosis.

Komal Jhaveri, MD, FACP, explains data on the frontline standard of care treatment approaches for ER-positive HER2-negative mBC.

Dr Komal Jhaveri highlights important data on oral SERDs for ER-positive HER2-negative mBC that was presented at recent meetings.

Komal Jhaveri, MD, FACP, discusses the role of capivasertib in ER-positive HER2-negative mBC and the design and outcomes of the CAPItello 291 trial.

Drs Jhaveri and Tarantino discuss the standard of practice for managing triple negative breast cancer.

Dr Jhaveri explains her thoughts on sequencing ADCs in the treatment of triple-negative breast cancer.

Komal Jhaveri, MD, FACP, explains the potential role ADCs may have in the future of breast cancer treatment.

Paolo Tarantino, MD, highlights additional abstracts from SABCS 2022 that he found particularly interesting.